Alessandro Gozzi received a M.Sc. degree in Biotechnology, and a PhD in biomedical imaging from the University of Verona. He later joined GlaxoSmithKline, a research-based pharmaceutical company, where he developed and implemented functional MRI methods to probe pharmacological mechanisms in preclinical models of CNS disorders. During his research, he has identified and described the circuital substrates modulated by centrally-active substances belonging to different pharmacological classes, and within multiple areas of experimental neuroscience (schizophrenia, depression, drug addiction etc.). He is currently group leader at the Istituto Italiano di Tecnologia in Rovereto (Italy), where he leads a MRI laboratory equipped with a preclinical 7 Tesla scanner for in vivo neuroimaging. His research interests focus on the application of advanced functional and structural MRI methods to describe healthy and pathological neurofunctional states, and the investigation of circuital basis of behavior and neuro-pharmacological action